plusbiome AG is pioneering a new class of anticancer medicines to deliver superior therapy outcomes compared to current treatment options.

Our therapeutic ambition is to regulate selectively microbiome-mediated mechanisms to drive effective anti-cancer immunity.


Products, services, technology

We provide access to our extensive expertise on the gut microbiome.

Cooperation possibilities

By focusing on the immune conditioning of the microbiome in cancer therapies we develop our portfolio of assets, which we are validating in pre-clinical studies. Reach out if you're interested in microbiome-mediated mechanisms of disease or are interested in licensing relevant enabling technologies.

Some insights
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland

You may also be interested in